One might expect that Acadia is keenly awaiting the results of Neuren's upcoming FDA meeting.
If Neuren could convince the FDA that that the PWS, PH and (hopefully) Angelman trials had proven NNZ-2591's safety and tolerance in patients, then could Acadia be in a position to go straight to a combined phase 2/3 trial for NNZ-2591 for Fragile X?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.000(0.00%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.32 | $7.219M | 577.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2968 | $12.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.57 | 540 | 1 |
View Market Depth
| Last trade - 16.16pm 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |